Prana moves forward on Alzheimer's treatment
Friday, 05 April, 2002
A treatment for Alzheimer's Disease is one step closer after the successful completion of a Phase II clinical trial by Prana Biotechnology for its drug PBT-1 (Iodochlorhydroxyquin).
The trial was performed on 32 patients. Half of the patients received the drug and half received a placebo, in a randomised double blind study. Full analysis of the results has not been completed.
Earlier studies in transgenic animals were published last year in the journal Neuron.
Prana's Executive Chairman, Geoffrey Kempler, said that as the current study was being prepared for publication, the company could not comment further on the results at this point in time.
Kempler said the company was pleased with the results, "It has given us a vote of confidence to keep moving forward."
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
